Prognostic models in hepatocellular carcinoma (HCC) and statistical methodologies behind them

Current Pharmaceutical Design

Volumn 13, Issue 15, 2007, Pages 1527-1532

  Dvorchik, I ^a,c   Demetris, A J ^a   Geller, D A ^a   Carr, B I ^a   Fontes, P ^a   Finkelstein, S D ^b   Cappella, N K ^a   Marsh, J W ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b RedPath Integrated Pathology   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cluster; Genotyping; Hepatocarcinoma; Microarrays; Prognostic models; Survival

Indexed keywords

AFLATOXIN;

ANALYSIS OF VARIANCE; ARTIFICIAL NEURAL NETWORK; CANCER MORTALITY; CANCER RECURRENCE; CANCER RESEARCH; CANCER STAGING; CARCINOGENESIS; CLINICAL PRACTICE; CLUSTER ANALYSIS; GENOTYPE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER SURGERY; LIVER TRANSPLANTATION; MATHEMATICAL MODEL; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REVIEW; RISK FACTOR; STATISTICAL ANALYSIS; SURVIVAL RATE;

ANALYSIS OF VARIANCE; CARCINOMA, HEPATOCELLULAR; CLUSTER ANALYSIS; DISEASE PROGRESSION; HUMANS; LIVER NEOPLASMS; MODELS, STATISTICAL; NEURAL NETWORKS (COMPUTER); OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RISK FACTORS;

EID: 34249850071     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207780765846     Document Type: Review

References (34)

1. Tang Z-Y, Yu Y-Q, Zhou X-D, Ma ZC, Yang BH, Lin ZY, et al. Treatment of unresectable primary liver cancer: with reference to cytoreduction and sequential resection. World J Surg 1995; 19: 47-52.
2. Nagasue N, Yukaya H, Hamada T, Hirose S, Kanashima R, Inokuchi K, et al. The natural history of hepatocellular carcinoma: a study of 100 untreated cases. Cancer 1984; 54: 1461-5.
3. Akriviadis EA, Llovet JM, Efremidis SC, Shouval D, Canelo R, Ringe B, et al. Hepatocellular carcinoma. Brit J Surg 1998; 85: 1319-31.
4. Calvet X, Bruix J, Gines P, Bru C, Sole M, Vilana R, et al. Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients. Hepatology 1990; 12: 753-60.
5. Okuda K. Hepatocellular carcinoma: recent progress. Hepatology 1992; 15: 948-63.
6. Okuda K, Fujimoto Y, Hanai A, Urano Y. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 1987; 47: 4967-72.
7. Zhang L, Cao Y, Song J. The correlation between integration of HBV X, S, Pre-S, C gene and the expression of oncogenes/tumor suppressor genes in primary hepatocellular carcinoma. Chung Hua Kan Tsang Ping Tsa Chih 1999; 7: 138-9.
8. Twu JS, Lai MY, Chen DS, Robinson WS. Activation of protooncogene C-jun by the X protein of hepatitis B virus. Virology 1993; 192: 346-9.
9. Martin P. Hepatocellular carcinoma: risk factors and natural history. Liver Transpl Surg 1998; 4: S87-91.
10. Yamauchi M, Nakahara M, Maezawa Y, Satoh S, Nishikawa F, Ohata M. Prevalence of hepatocellular carcinoma in patients with alcoholic cirrhosis and prior exposure to hepatitis C. Am J Gastroenterol 1993; 88: 39-43.
11. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985; 313: 1256-9.
12. Vautier G, Bomford AB, Portmann BC, Metivier E, Williams R, Ryder SD. P53 mutations in British patients with hepatocellular carcinoma: clustering in genetic hemochromatosis. Gastroenterology 1999; 117: 154-60.
13. Okuda K, Ohtsuki T, Obata H. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer 1985; 56: 918-28.
14. Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998; 28: 751-5.
15. Cancer of the Liver Italian Program (CLIP) Investigators. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000; 31: 840-5
16. Mazzaferro V, Regala E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334(11): 693-9.
17. Yao FY, Ferrell L, Bass NM, Watson J, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33(6): 1394-403.
18. Marsh JW, Dvorchik I, Subotin M, Ballan V, Rakela J, Popechitelev EP, et al. Predicting the risk of tumor recurrence following transplantation for HCC. Hepatology 1997; 26(6): 1689-90.
19. Marsh JW, Dvorchik I, Casavilla A, Fung JJ, Iwatsuki S. Should reimbursement be denied for liver transplantation in patients with hepatocellular carcinoma? [letter]. JAMA 1997; 278(3): 203-5.
20. Kirimlioglu H, Dvorchik I, Ruppert K, Finkelstein S, Marsh JW, Iwatsuki S, et al. Hepatocellular carcinomas in native livers from patients treated with orthotopic liver transplantation: biologic and therapeutic implications. Hepatology 2001; 34(3): 502-10.
21. Finkelstein SD, Sayegh R, Christensen S, Swalsky PA. Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type. Cancer 1993; 71(12): 3827-38.
22. Finkelstein SD, Marsh JW, Demetris AJ, Swalsky PA, Sasatomi E, Bonham A, et al. Microdissection-based allelotyping discriminates de novo tumor from intrahepatic spread in hepatocellular carcinoma. Hepatology 2003; 37(4): 871-9.
23. Klein JP, Moeschberger ML. Survival analysis: Techniques for censored and truncated data. Springer-Verlag New York, Inc. 1997.
24. Drǧhici S. Data analysis tools for DNA microarrays. chapman & Hall/CRC mathematical biology and medicine series, 2003.
25. DeRisi JL, Penland L, Brown PO, Bittner ML, Meltzer PS, Ray M, et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet 1996; 14(4): 457-60.
26. Schena M, Shalon D, Davis R. Brown P. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995; 270: 467-70.
27. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979; 6: 65-70.
28. Benjamini Y. and Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Royal Stat Soc B 1995; 57(1): 289-300.
29. Westfall PH, Young SS. Resampling-based multiple testing: Examples and methods for p-value adjustment. Wiley, New York, 1993.
30. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98(9): 5116-21.
31. Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004; 40(3): 667-76.
32. Ohno T. Autologous formalin-fixed tumor vaccine. Curr Pharm Des 2005; 11(9): 1181-8.
33. Weber T, Auer J, Eber B. The diagnostic and prognostic value of brain natriuretic peptide and aminoterminal (nt)-pro brain natriuretic peptide. Curr Pharm Des 2005; 11(4): 511-25.
34. Wilson SS, Crawford ED. Controversies of androgen ablation therapy for metastatic prostate cancer. Curr Pharm Des 2006; 12(7): 799-805.